The OTC industry is well-positioned to seize opportunities across the self-care space, executives at the recent Consumer Healthcare Products Association Annual Executive Conference shared with attendees. Those opportunities will be driven by greater consumer engagement and the growing realization around how much healthcare value can be drawn from expanding OTC access.

That sets the stage for some pretty favorable growth across a $38.3 billion industry. According to an Edelman in Health survey, use of over-the-counter medicines is already prevalent among Americans — almost 85% of Americans reported regular use of an OTC remedy. Convenience, efficacy and value were three of the key factors behind that prevalence, as noted in a special report compiled by DSN.

Amid a tide of automatic spending cuts resulting from the failure of Congress and the White House to agree on a budget, the generic drug lobby has offered some suggestions to generate savings.

Medication-information website Drugs.com has launched a mobile app that includes access to personal medication records, drug-interaction lists and breaking health news, the company said Friday.

Just about every healthcare practitioner recommends over-the-counter medicines to their patients. And nearly 3-out-of-4 make that OTC recommendation as the first therapy option, according to a recent survey released by the Consumer Healthcare Products Association.

This is another proof point that OTC medicines play an important role in holding down cost.

Prescription-only pseudoephedrine laws result in well more than $278 million in additional burdens to taxpayers, according to a study published by Matrix Global Advisors.

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The Consumer Healthcare Products Association on Friday released a statement regarding a poll released last week by the Asthma and Allergy Foundation of America.

The battle over "pay for delay" continues to heat up, and its resolution likely won't come until the nation's highest court decides on the legality of the practice.

Alabama's Supreme Court ruled in January that brand-name drug companies could be sued if patients suffer complications from generic versions of their medicines, according to published reports.

It's been long accepted that politics makes strange bedfellows. That's certainly the case with the reauthorization in 2012 of the Prescription Drug User Fee Act.

The world market for generic drugs will jump more than 15% this year and reach a global total of $127.8 billion, predicted a report from British market research firm Visiongain.

Pharmacy benefit managers are becoming increasingly adept at leveraging the power of generics to save client healthcare dollars and improve their own standing, reports indicated.